PMID- 25459315
OWN - NLM
STAT- MEDLINE
DCOM- 20151130
LR  - 20150216
IS  - 1532-818X (Electronic)
IS  - 0196-0709 (Linking)
VI  - 36
IP  - 2
DP  - 2015 Mar-Apr
TI  - Postoperative radiotherapy for laryngeal carcinoma: the prognostic role of 
      subcellular Maspin expression.
PG  - 184-9
LID - S0196-0709(14)00254-3 [pii]
LID - 10.1016/j.amjoto.2014.10.027 [doi]
AB  - PURPOSE: Reported outcomes of postoperative radiotherapy (PORT) for laryngeal 
      squamous cell carcinoma (LSCC) have varied and sometimes been disappointing. The 
      aim of the present preliminary study was to investigate whether a given 
      immunohistochemical pattern of Maspin expression in laryngeal carcinoma cells 
      could be prognostically associated with response to PORT. MATERIALS AND METHODS: 
      Thirty-two consecutive patients treated for LSCC with primary surgery and PORT. 
      The subcellular (nuclear vs non-nuclear) pattern of Maspin expression was 
      assessed immunohistochemically on LSCC surgical specimens and analyzed in 
      relation to recurrence rate (RR) and disease-free survival (DFS). RESULTS: A 
      non-nuclear Maspin expression was found in 23 of 32 cases (72%), and all 
      recurrences (17 cases) occurred in this subgroup of patients. A non-nuclear 
      Maspin expression was strongly associated with recurrence [p = 0.0002, hazard 
      ratio (HR) 5.58] and a shorter DFS (p = 0.0004) after PORT for LSCC. Even in N0 
      patients, a non-nuclear Maspin expression was associated with a significantly 
      higher RR (p = 0.04, HR 1.42) and a shorter DFS (p = 0.02). Among the common 
      clinic-pathological parameters considered, only N stage showed a trend toward an 
      association with prognosis in terms of DFS (p = 0.08). CONCLUSION: Assessing 
      subcellular patterns of Maspin expression in LSCC specimens could identify 
      patients less likely to respond to PORT, who might benefit from combined 
      chemo-radiotherapy to improve the efficacy of adjuvant protocols.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Lionello, Marco
AU  - Lionello M
AD  - Department of Neurosciences, Otolaryngology Section, University of Padova, 
      Padova, Italy. Electronic address: marcolionello@email.it.
FAU - Blandamura, Stella
AU  - Blandamura S
AD  - Department of Medicine, DIMED, University of Padova, Padova, Italy.
FAU - Staffieri, Claudia
AU  - Staffieri C
AD  - Department of Neurosciences, Otolaryngology Section, Treviso Branch, University 
      of Padova, Treviso, Italy.
FAU - Tealdo, Giulia
AU  - Tealdo G
AD  - Department of Neurosciences, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - Giacomelli, Luciano
AU  - Giacomelli L
AD  - Department of Medicine, DIMED, University of Padova, Padova, Italy.
FAU - Marchese Ragona, Rosario
AU  - Marchese Ragona R
AD  - Department of Neurosciences, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - de Filippis, Cosimo
AU  - de Filippis C
AD  - Department of Neurosciences, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - Staffieri, Alberto
AU  - Staffieri A
AD  - Department of Neurosciences, Otolaryngology Section, University of Padova, 
      Padova, Italy.
FAU - Marioni, Gino
AU  - Marioni G
AD  - Department of Neurosciences, Otolaryngology Section, University of Padova, 
      Padova, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141022
PL  - United States
TA  - Am J Otolaryngol
JT  - American journal of otolaryngology
JID - 8000029
RN  - 0 (SERPIN-B5)
RN  - 0 (Serpins)
SB  - IM
MH  - Aged
MH  - Carcinoma, Squamous Cell/genetics/mortality/*radiotherapy/surgery
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/genetics/mortality/*radiotherapy/surgery
MH  - Laryngectomy/methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness/pathology
MH  - Neoplasm Recurrence, Local/*mortality/pathology
MH  - Neoplasm Staging
MH  - Postoperative Period
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Radiotherapy, Adjuvant
MH  - Risk Assessment
MH  - Serpins/*genetics
MH  - Statistics, Nonparametric
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2014/12/03 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/09/27 00:00 [received]
PHST- 2014/10/15 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S0196-0709(14)00254-3 [pii]
AID - 10.1016/j.amjoto.2014.10.027 [doi]
PST - ppublish
SO  - Am J Otolaryngol. 2015 Mar-Apr;36(2):184-9. doi: 10.1016/j.amjoto.2014.10.027. 
      Epub 2014 Oct 22.